Alzheimer disease therapy: Can the amyloid cascade be halted?

被引:134
作者
Golde, TE [1 ]
机构
[1] Mayo Clin Jacksonville, Dept Neurosci, Jacksonville, FL 32224 USA
关键词
D O I
10.1172/JCI200317527
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cognitive enhancers that target acetylcholinesterase remain the only FDA-approved therapies for the treatment of the cognitive decline in AD. Such therapy is unlikely to modify the course of the disease to any significant extent. In contrast, therapies currently being developed that are based on an increased understanding of the pathogeneses of AD are likely to have disease-modifying effects. Given the plethora of potential targets, it is likely that successful anti-Aβ therapies will emerge. The major challenge that remains is to show that such therapies actually alter cognitive decline in humans. The medical community should be cautious in evaluating the efficacy of anti-Aβ drugs, as they may not show such disease-modifying effects when given in therapeutic trials. To restate the analogy to atherosclerotic disease, by the time a patient is experiencing angina, the patient needs a bypass or angioplasty, not a cholesterol-lowering agent (although after intervention such an agent would be appropriate). Similarly, in AD, by the time a patient is symptomatic, Aβ-lowering therapies may not be effective. We must hope that advances in diagnostic prediction and monitoring of disease progression proceed with a pace that equals the advances currently being made in developing AD therapeutics that target Aβ. If they do, then it is likely that AD will become manageable through a combination of presymptomatic screening, early therapeutic intervention, and vigilant monitoring of the effectiveness of treatment.
引用
收藏
页码:11 / 18
页数:8
相关论文
共 105 条
[81]   The genetics of Alzheimer's disease [J].
Rubinsztein, DC .
PROGRESS IN NEUROBIOLOGY, 1997, 52 (06) :447-454
[82]   Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse [J].
Schenk, D ;
Barbour, R ;
Dunn, W ;
Gordon, G ;
Grajeda, H ;
Guido, T ;
Hu, K ;
Huang, JP ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, M ;
Liao, ZM ;
Lieberburg, I ;
Motter, R ;
Mutter, L ;
Soriano, F ;
Shopp, G ;
Vasquez, N ;
Vandevert, C ;
Walker, S ;
Wogulis, M ;
Yednock, T ;
Games, D ;
Seubert, P .
NATURE, 1999, 400 (6740) :173-177
[83]   Amyloid-β immunotherapy for Alzheimer's disease:: the end of the beginning [J].
Schenk, D .
NATURE REVIEWS NEUROSCIENCE, 2002, 3 (10) :824-828
[84]   Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease [J].
Scheuner, D ;
Eckman, C ;
Jensen, M ;
Song, X ;
Citron, M ;
Suzuki, N ;
Bird, TD ;
Hardy, J ;
Hutton, M ;
Kukull, W ;
Larson, E ;
LevyLahad, E ;
Viitanen, M ;
Peskind, E ;
Poorkaj, P ;
Schellenberg, G ;
Tanzi, R ;
Wasco, W ;
Lannfelt, L ;
Selkoe, D ;
Younkin, S .
NATURE MEDICINE, 1996, 2 (08) :864-870
[85]   Elevated plasma amyloid β-peptide 1-42 and onset of dementia in adults with Down syndrome [J].
Schupf, N ;
Patel, B ;
Silverman, W ;
Zigman, WB ;
Zhong, N ;
Tycko, B ;
Mehta, PD ;
Mayeux, R .
NEUROSCIENCE LETTERS, 2001, 301 (03) :199-203
[86]   Presenilin-1 and-2 are molecular targets for γ-secretase inhibitors [J].
Seiffert, D ;
Bradley, JD ;
Rominger, CM ;
Rominger, DH ;
Yang, FD ;
Meredith, JE ;
Tang, Q ;
Roach, AH ;
Thompson, LA ;
Spitz, SM ;
Higaki, JN ;
Prakash, SR ;
Combs, AP ;
Copeland, RA ;
Arneric, SP ;
Hartig, PR ;
Robertson, DW ;
Cordell, B ;
Stern, AM ;
Olson, RE ;
Zaczek, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (44) :34086-34091
[87]   Alzheimer's disease: Genes, proteins, and therapy [J].
Selkoe, DJ .
PHYSIOLOGICAL REVIEWS, 2001, 81 (02) :741-766
[88]   In vivo reversal of amyloid-β lesions in rat brain [J].
Sigurdsson, EM ;
Permanne, B ;
Soto, C ;
Wisniewski, T ;
Frangione, B .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2000, 59 (01) :11-17
[89]   Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons [J].
Simons, M ;
Keller, P ;
De Strooper, B ;
Beyreuther, K ;
Dotti, CG ;
Simons, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (11) :6460-6464
[90]   In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease [J].
Skovronsky, DM ;
Zhang, B ;
Kung, MP ;
Kung, HF ;
Trojanowski, JQ ;
Lee, VMY .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (13) :7609-7614